MarketWatch

(CNW) A World-First in Neonatal Care: Japan Approves Prolacta Bioscience's 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants

The MarketWatch News Department was not involved in the creation of this content. Japan's Ministry of Health, Labour and Welfare (MHLW) Approves PreemieFort(R) Enteral Solution as Prescription ...
Morningstar

A World-First in Neonatal Care: Japan Approves Prolacta Bioscience's 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants

DUARTE, Calif., Feb. 18, 2026 /PRNewswire/ -- Prolacta Bioscience® today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved PreemieFort® Enteral Solution, a 100% human ...
MarketWatch

A World-First in Neonatal Care: Japan Approves Prolacta Bioscience's 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants

The MarketWatch News Department was not involved in the creation of this content. Japan's Ministry of Health, Labour and Welfare (MHLW) Approves PreemieFort(R) Enteral Solution as Prescription ...
Yahoo Finance

A World-First in Neonatal Care: Japan Approves Prolacta Bioscience's 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants

The landmark regulatory decision validates the critical role of Prolacta's 100% human milk-based fortifiers for the most fragile infants and sets a powerful precedent for neonatal intensive care units ...